RUBY - Rubius Therapeutics appoints new operations chief

Rubius Therapeutics (NASDAQ:RUBY) appoints Dannielle Appelhans as COO, effective August 9, 2021. She will oversee corporate strategy and technical operations. Most recently, Ms. Appelhans served as senior vice president of technical operations and chief technical officer at Novartis Gene Therapies, where she oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio.

For further details see:

Rubius Therapeutics appoints new operations chief